OCIAD1
Reaktivität: Maus, Ratte
WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro)
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA. Western blot: 1 - 2 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL
Buffer
PBS containing 0.02 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
-20 °C
Informationen zur Lagerung
Store the antibody (in aliquots) at -20 °C.
Target
OCIAD1
(OCIA Domain Containing 1 (OCIAD1))
Andere Bezeichnung
OCIAD1 / OCIA
Hintergrund
OCIAD1 was identified via immunoscreening of an ovarian carcinoma cDNA library from ovarian cancer patients and is expressed in multiple tissues including ovary, placenta, brain, testis, prostate, and mammary gland. Two isoforms of OCIAD1 are known to exist, the shorter isoform is restricted to the central nervous system. OCIAD1 is a transmembrane protein whose overexpression in HEY ovarian cancer cells increased lysophosphatidic acid- (LPA-)induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin10/11. This adhesion is not blocked by LY294002 and GF109203X, suggesting that OCIAD1 does not use protein kinase C and PI3 kinase signaling pathways to exert its effect on adhesion.Synonyms: OCIA domain-containing protein 1, Ovarian carcinoma immunoreactive antigen